Table 2

DMARDs and oral glucocorticoid use among subjects with rheumatoid arthritis in the MCBS, 2001 to 2006

2001

2002

2003

2004

2005

2006


Number of patients

291

334

316

244

148

70

Any DMARDS

82 (28%)

83 (25%)

85 (27%)

88 (36%)

55(37%)

25 (36%)

Non-biologic DMARD

80 (27%)

82 (25%)

80 (25%)

85 (35%)

51 (35%)

22 (31%)

Methotrexate

49 (17%)

47 (14%)

42 (13%)

50 (20%)

31 (21%)

12 (17%)

Sulfasalazine

8 (3%)

5 (2%)

7 (2%)

5 (2%)

1 (0.5%)

1 (0.5%)

Hydroxychloroquine

25 (9%)

29 (9%)

29 (9%)

27 (11%)

15 (10%)

9 (13%)

Azathioprine

5 (2%)

3 (1%)

2 (1%)

3 (1%)

2 (1%)

0 (0%)

Leflunomide

6 (2%)

11 (3%)

12 (4%)

13 (5%)

8 (5%)

2 (3%)

Gold

0 (0%)

1 (0.3%)

2 (0.6%)

0 (0%)

0 (0%)

1 (1.4%)

Others

0 (0%)

0 (0%)

0 (0%)

1 (0.4%)

0 (0%)

0 (0%)

Biologic DMARD, any

6 (2%)

5 (2%)

11 (3%)

10 (4%)

14 (9%)

5 (7%)

Etanercept

3 (1%)

4 (1%)

8 (3%)

5 (2%)

6 (4%)

3 (4%)

Adalimumab

0 (0%)

0 (0%)

2 (1%)

3 (1%)

7 (5%)

2 (3%)

Infliximab

3 (1%)

1 (0.3%)

1 (0.3%)

2 (0.8%)

1 (07%)

0 (0%)

Anakinra

0 (0%)

1 (0.3%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

Oral steroid use, any

89 (31%)

94 (28%)

97 (31%)

82 (34%)

54(36%)

26 (37%)

Oral steroid use, only

50 (17%)

60 (18%)

60 (21%)

50 (18%)

41 (28%)

20 (29%)


Results are presented as number (%) of patients. Percentages are based on the number for a given year. They do not add up to 100% because the rows are not mutually exclusive categories. The sample size is greater than 509 because respondents were included in all years after they met the rheumatoid arthritis definition. However, the sample size decreased over time because of the requirement for at least 12 months of follow-up after a diagnosis of rheumatoid arthritis. DMARD, disease modifying anti-rheumatic drug; MCBS, Medicare Current Beneficiary Survey.

Solomon et al. Arthritis Research & Therapy 2013 15:R43   doi:10.1186/ar4201

Open Data